Marek Kania, M.D., M.B.A.

Biopharmaceutical Executive Leader, committed to build effective and efficient startup organizations, drug development programs and product commercialization, which are focused on highest value creation for patients, physicians and payors. Most recently Dr. Kania served in a dual role as Executive VP, Managing Director and Chief Medical Officer for HUTCHMED Int., member of the C-Suite, Executive Committee of 2.5-3bio USD market cap company. Dr. Kania designed, built and led International, which focused on driving portfolio development, launching new products and creating high value for patients, providers and payors. Within 4.5 years he attracted and built the entire organization from zero, to approx.150 individuals across all functions, opened 6 global clinical programs, more than 20 trials from phase 1 to phase 3s. Dr. Kania managed the entire entity P&L. He was responsible for building capabilities from a ground up and leading company’s global organization across the entire international enterprise, across all functions. Several new US INDs were submitted, and programs initiated, with two late phase programs including global regulatory NDA/MAA submissions. Fruquitinib global registration phase 3 study, FRESCO 2 designed and executed in record time during most restrictive global pandemic related limitations. Trial resulted in global practice change results in metastatic colorectal cancer, with US, EU and Japan approvals. FRESCO2 Positive results led to a global licensing deal with Takeda Oncology, with 400mio USD upfront payment and potential to generate 1.13bio USD in milestones payments. Previous to this position, during 25 years’ experience at Eli Lilly and Company held several senior management roles, last few as Vice President of Medical Policy and Strategy across the enterprise and VP of Global Med. Affairs and Late Phase Product Development for Lilly Oncology and Global Oncology Product development Leader. At Eli Lilly and Company main areas of Dr. Kania experience spanned across general management, global oncology clinical research and development, and global regulatory and medical affairs, leading teams to launch multiple new oncology brands; corporate enterprise-wide medical policy and strategy, quality assurance, global strategic commercial, marketing. Specialties: General Management of the Startup Organization, CMO, Oncology Global Clinical Research & Development, Global Medical and Regulatory Affairs Leadership, New Product Launch Capabilities. Leading Leaders, Corporate Leadership, Enterprise level Medical Policies and Procedures